Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">NovaBay Pharma initiated with a Buy at Rodman & Renshaw; tgt $6 (4.10)Rodman & Renshaw initiates NBY with a Buy and price target of $6. NovaBay's sole marketed product, Avenova, is an eyelid and eyelash cleaner for treatment of blepharitis (eyelid inflammation) and dry eye disease (DED). Firm feels Avenova is convenient to use, clears eyelid and eyelash infections within a few days to a few weeks, and avoids the stinging or burning sensations associated with various over-the-counter (OTC) products used to clean eyelids because these products contain soaps and/or detergents. Since introduction, it has grown rapidly, generating $4.4M in 2015 sales and $11.8M in 2016 sales. Firm projects $20.4M in 2017 and $28.8M in 2018 top-line revenue for NovaBay. Avenova is protected by patent claims expiring in 2028.</td> </tr></table>"